Skip to content
Sign in

OCUL · NASDAQ

Ocular Therapeutix (OCUL) Stock Price & Fundamentals

$346.93−0.63%−$2.19End-of-day price as of Oct 9, 2026

Ocular Therapeutix (OCUL) closed at $346.93 on Oct 9, 2026, down 0.63% from the previous close of $349.12.

Share price, past year

1Y +8.20%

52-week range $315.87 – $361.48. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$346.93
Sep 30, 2026$333.47
Aug 31, 2026$324.88
Jul 31, 2026$334.86
Jun 30, 2026$336.99
May 29, 2026$336.35
Apr 30, 2026$323.99
Mar 31, 2026$343.69
Feb 27, 2026$337.70
Jan 30, 2026$350.59
Dec 31, 2025$341.36
Nov 28, 2025$333.60
Oct 31, 2025$318.94

Key statistics

Market cap
$76.18B
P/E (TTM)
—
EPS (TTM)
−$1.40
Revenue (TTM)
$52.05M
Net income (TTM)
−$301.45M
Shares outstanding
219.6M
Dividend yield
—
52-week range
$315.87 – $361.48

Ocular Therapeutix's market cap is $76.18B, based on a share price of $346.93 and 219.6M shares outstanding as of Jun 30, 2026.

Financials

Ocular Therapeutix reported revenue of $51.95M for fiscal 2025, down 18.47% from fiscal 2024.

Ocular Therapeutix reported a net loss of $265.94M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Ocular Therapeutix annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$51.95M−18.5%−$265.94M−511.9%−$1.42−$216.89M
FY2024ended Dec 31, 2024$63.72M+9.0%−$193.51M−303.7%−$1.22−$135.97M
FY2023ended Dec 31, 2023$58.44M+13.5%−$80.74M−138.1%−$1.02−$76.32M
FY2022ended Dec 31, 2022$51.49M+18.3%−$71.04M−138.0%−$0.97−$63.32M
FY2021ended Dec 31, 2021$43.52M+150.1%−$6.55M−15.1%−$0.98−$66.74M
FY2020ended Dec 31, 2020$17.40M+311.7%−$155.64M−894.3%−$2.56−$54.40M
FY2019ended Dec 31, 2019$4.23M+112.4%−$86.37M−2,043.3%−$1.91−$79.82M
FY2018ended Dec 31, 2018$1.99M+3.5%−$59.98M−3,014.0%−$1.57−$51.12M
FY2017ended Dec 31, 2017$1.92M+1.9%−$63.39M−3,296.2%−$2.20−$58.73M
FY2016ended Dec 31, 2016$1.89M—−$44.70M−2,369.0%−$1.80−$35.92M
Ocular Therapeutix quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$13.48M−$78.76M−$0.35
Q1 FY2026ended Mar 31, 2026$10.79M−$88.61M−$0.40
Q4 FY2025ended Dec 31, 2025$13.25M−$64.65M−$0.27
Q3 FY2025ended Sep 30, 2025$14.54M−$69.42M−$0.38
Q2 FY2025ended Jun 30, 2025$13.46M−$67.81M−$0.39
Q1 FY2025ended Mar 31, 2025$10.70M−$64.05M−$0.38
Q4 FY2024ended Dec 31, 2024$17.08M−$48.39M−$0.25
Q3 FY2024ended Sep 30, 2024$15.43M−$36.49M−$0.22

Company profile

Name
Ocular Therapeutix, Inc.
Ticker
OCUL
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
14 Crosby Drive, 3rd Floor, Bedford, MA 01730
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001393434

Recent SEC filings

Frequently asked questions

What is Ocular Therapeutix's stock price?

Ocular Therapeutix (OCUL) closed at $346.93 on Oct 9, 2026, down 0.63% from the previous close of $349.12.

What is Ocular Therapeutix's market cap?

Ocular Therapeutix's market cap is $76.18B, based on a share price of $346.93 and 219.6M shares outstanding as of Jun 30, 2026.

How much revenue does Ocular Therapeutix make?

Ocular Therapeutix reported revenue of $51.95M for fiscal 2025, down 18.47% from fiscal 2024.

Does Ocular Therapeutix pay a dividend?

Ocular Therapeutix's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Ocular Therapeutix, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures